High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Delphine Rea,Laurence Legros,Emmanuel Raffoux,X Thomas,Pascal Turlure,Sébastien Maury,Brigitte Dupriez,A Pigneux,B. Choufi,Oumedaly Reman,D Stéphane,Bruno Royer,M. Vigier,Mario Ojeda-Uribe,Christian Recher,Hervé Dombret,Françoise Huguet,Philippe Rousselot

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

2006

Delphine Rea
Laurence Legros
Emmanuel Raffoux
X Thomas
Pascal Turlure
Sébastien Maury
Brigitte Dupriez
A Pigneux
B. Choufi
Oumedaly Reman
D Stéphane
Bruno Royer
M. Vigier
Mario Ojeda-Uribe
Christian Recher
Hervé Dombret
Françoise Huguet
Philippe Rousselot

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

Keywords:

Acute lymphocytic leukemia
Regimen
Cancer research
Mesylate
Myeloid leukemia
Vincristine
Imatinib
Acute leukemia
Medicine
Chemotherapy
imatinib mesylate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations